AXL and non-small cell lung carcinoma: EMT-transformed non-small cell lung cancer (NSCLC) cells resistant to EGF-R treatment express high levels of Axl to bypass the blocked EGF-R, explaining their susceptibility towards pharmacological Axl inhibition [47,72].